Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?

Eli Lilly and Company (NYSE:LLY) has become one of the pharmaceutical industry's most important growth stories, but its valuation presents a harder question than whether demand for obesity treatments will continue to rise. Investors must decide how much of that growth remains ahead, and how much is already reflected in the share price. Lilly's shares closed at $1,188.72 on October 7, 2026, according to Yahoo Finance, approximately 41% above their October 7, 2025 closing price of $843.63, based on Yahoo Finance's historical data. That substantial gain reflects a business whose earnings potential has expanded rapidly, but it also raises the bar for future results.